PUBLIC HEALTH IMPACT OF NIRSEVIMAB AGAINST LOWER RESPIRATORY INFECTIONS ASSOCIATED WITH RESPIRATORY SYNCYTIAL VIRUS AMONG CHINESE INFANTS

被引：0
|
作者：
Lai, X. [1 ]
Ma, Y. [2 ]
Zou, W. [3 ]
Soudani, S. [4 ]
Fang, H. [2 ]
机构：
[1] Peking Univ, Oxford, England
[2] Peking Univ, Beijing, Peoples R China
[3] Sanofi, Beijing, Peoples R China
[4] Sanofi, Lyon, France
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EPH206
引用
收藏
页码：S241 / S241
页数：1
相关论文
共 50 条
  • [1] Will nirsevimab be the holy grail for prevention of respiratory syncytial virus lower respiratory tract infections in infants?
    Homaira, Nusrat
    TRANSLATIONAL PEDIATRICS, 2024, 13 (03) : 525 - 529
  • [2] Does nirsevimab prevent lower respiratory infections caused by respiratory syncytial virus?
    Sullivan, Kelsey
    Sullivan, Brynne
    JOURNAL OF PERINATOLOGY, 2024, 44 (05) : 767 - 769
  • [3] Respiratory syncytial virus - associated lower respiratory tract infections in hospitalized infants
    D'Elia, C
    Siqueira, MM
    Portes, SA
    Sant'Anna, CC
    REVISTA DA SOCIEDADE BRASILEIRA DE MEDICINA TROPICAL, 2005, 38 (01) : 7 - 10
  • [4] Nirsevimab for prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and Infants
    不详
    AUSTRALIAN PRESCRIBER, 2024, 47 (03) : 102 - 103
  • [5] Nirsevimab Immunization to Prevent Respiratory Syncytial Virus-Associated Lower Respiratory Tract Infections in Infants and Children up to 24 Months of Age
    Cieslak, Chelsea M.
    NURSING FOR WOMENS HEALTH, 2024, 28 (01) : 75 - 79
  • [6] MODELED IMPACT OF NIRSEVIMAB AGAINST RESPIRATORY SYNCYTIAL VIRUS (RSV) AMONG UK INFANTS EXPERIENCING THEIR FIRST RSV SEASON
    Beuvelet, M.
    Davidson, C.
    Hudson, R.
    Kieffer, A.
    VALUE IN HEALTH, 2022, 25 (01) : S125 - S125
  • [7] Early estimates of nirsevimab immunoprophylaxis effectiveness against hospital admission for respiratory syncytial virus lower respiratory tract infections in infants, Spain, October 2023 to January 2024
    Lopez-Lacort, Monica
    Munoz-Quiles, Cintia
    Mira-Iglesias, Ainara
    Lopez-Labrador, F. Xavier
    Mengual-Chulia, Beatriz
    Fernandez-Garcia, Carlos
    Carballido-Fernandez, Mario
    Pineda-Caplliure, Ana
    Mollar-Maseres, Juan
    Benavent, Maruan Shalabi
    Sanz-Herrero, Francisco
    Zornoza-Moreno, Matilde
    Perez-Martin, Jaime Jesus
    Alfayate-Miguelez, Santiago
    Crespo, Rocio Perez
    Sanchez, Encarnacion Bastida
    Menasalvas-Ruiz, Ana Isabel
    Tellez-Gonzalez, M. Cinta
    Soto, Samuel Esquiva
    Saravia, Carlos Del Toro
    Sanz-Munoz, Ivan
    Eiros, Jose Maria
    Del Pozo, Vanesa Matias
    Toquero-Asensi, Marina
    Pastor-Villalba, Eliseo
    Lluch-Rodrigo, Jose Antonio
    Diez-Domingo, Javier
    Orrico-Sanchez, Alejandro
    EUROSURVEILLANCE, 2024, 29 (06)
  • [8] Breakthrough therapy designation of nirsevimab for the prevention of lower respiratory tract illness caused by respiratory syncytial virus infections (RSV)
    Bergeron, Harrison C.
    Tripp, Ralph A.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2022, 31 (01) : 23 - 29
  • [9] POTENTIAL PUBLIC HEALTH IMPACT OF BIVALENT RESPIRATORY SYNCYTIAL VIRUS PREFUSION F (RSVPREF) MATERNAL VACCINE FOR PREVENTION OF RESPIRATORY SYNCYTIAL VIRUS (RSV) LOWER RESPIRATORY TRACT ILLNESS (LRTI) AMONG CANADIAN INFANTS
    Goyette, A.
    Averin, A.
    Atwood, M.
    Kutrieb, E.
    Yahia, Ait N.
    Elsobky, M.
    Beltran, Grajales A. G.
    Law, A.
    Weycker, D.
    VALUE IN HEALTH, 2023, 26 (12) : S221 - S222
  • [10] An evaluation of the emerging interventions against Respiratory Syncytial Virus (RSV)-associated acute lower respiratory infections in children
    Nair, Harish
    Verma, Vasundhara R.
    Theodoratou, Evropi
    Zgaga, Lina
    Huda, Tanvir
    Simoes, Eric A. F.
    Wright, Peter F.
    Rudan, Igor
    Campbell, Harry
    BMC PUBLIC HEALTH, 2011, 11
12345